Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E, particularly in the forms of beta and delta tocopherols, has been explored for its potential to reduce certain side effects of chemotherapy, notably chemotherapy-induced peripheral neuropathy (CIPN) and oral mucositis. The scientific rationale is based on Vitamin E’s antioxidant properties, which may help protect normal tissues from oxidative damage caused by chemotherapeutic agents. Several small randomized controlled trials and meta-analyses have investigated the use of Vitamin E (mainly alpha-tocopherol, but some data include mixed tocopherols) for this purpose. Some studies suggest a modest benefit, particularly in reducing the severity and incidence of CIPN, while others show little or no effect. The evidence is inconsistent and often limited by small sample sizes, short follow-up periods, and varying dosages and forms of Vitamin E used. Additionally, there are concerns that antioxidant supplementation may potentially reduce the efficacy of chemotherapy by protecting tumor cells as well as normal cells, although this risk is still under investigation. Major clinical guidelines generally do not recommend routine use of Vitamin E supplements during chemotherapy due to insufficient high-quality evidence and the potential for harm. In summary, while there is some preliminary scientific evidence suggesting a possible benefit of Vitamin E (including beta and delta tocopherols) in reducing certain chemotherapy side effects, the overall support is weak and inconclusive.

More about Vitamin E (beta and delta tocopherols)
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Vitamin E (beta and delta tocopherols)

Products containing Vitamin E (beta and delta tocopherols)